The immunologicals group of the Binding Site, San Diego, has added three new native Bordetella pertussis antigens to its broad offering of products for in vitro diagnostic (IVD) manufacturing and research applications.
The Bordetella pertussis filamentous hemagglutinin antigen (FHA), Bordetella pertussis toxin antigen, and Bordetella pertussis whole-cell antigen have each been expressly designed for use as integral components of solid-phase enzyme immunoassay procedures, including enzyme-linked immunosorbent assays. Availability of the antigens will benefit biopharmaceutical, clinical, drug-discovery, and life science researchers, as well as manufacturers of IVD test kits.
Each of the antigens exhibits exceptional purity as a result of exclusive chromatographic manufacturing techniques, while demonstrating exceptional lot-to-lot consistency and high degrees of activity and specificity. They all feature shelf-life stability of 10 years from the date of manufacture and are offered in a standard-sized 1.0 mg vial, with bulk packaging configurations also available. Evaluation samples for testing are available upon request.
For further information, visit the Binding Site.
